Evidence map›Paper›PMID 24933634›Full record

ArticleInternational journal of molecular sciences2014

Brain metastases from lung cancer show increased expression of DVL1, DVL3 and beta-catenin and down-regulation of E-cadherin.

Anja Kafka, Davor Tomas, Vili Beroš, Hrvoje Ivan Pećina, Martina Zeljko, Nives Pećina-Šlaus

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 54 citations in OpenAlex.

  1. Oncology Clinical Trials Targeting Members of the Cadherin Superfamily: A Review.Journal of immunotherapy and precision oncology · 2025
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Decoding the Role of DVL1 in Intracranial Meningioma.International journal of molecular sciences · 2021
    Article
  8. Article
  9. TWIST1 upregulation affects E-cadherin expression in brain metastases.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Anja KafkaLaboratory of Neuro-Oncology, Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Salata 12, 10000 Zagreb, Croatia. anja.kafka@mef.hr.
Davor TomasLjudevit Jurak Department of Pathology, University Hospital "Sisters of Charity", 10000 Zagreb, Croatia. davor.tomas@kbcsm.hr.
Vili BerošDepartment of Neurosurgery, University Hospital "Sisters of Charity", 10000 Zagreb, Croatia. viliberos@gmail.com.
Hrvoje Ivan PećinaDepartment of Radiology, University Hospital "Sisters of Charity", 10000 Zagreb, Croatia. hipecina@gmail.com.
Martina ZeljkoLaboratory of Neuro-Oncology, Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Salata 12, 10000 Zagreb, Croatia. martina.zeljko2@gmail.com.
Nives Pećina-ŠlausLaboratory of Neuro-Oncology, Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Salata 12, 10000 Zagreb, Croatia. nina@mef.hr.
University of Zagreb · HRSisters of Charity Hospital · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The susceptibility of brain to secondary formation from lung cancer primaries is a well-known phenomenon. In contrast, the molecular basis for invasion and metastasis to the brain is largely unknown. In the present study, 31 brain metastases that originated from primary lung carcinomas were analyzed regarding over expression of Dishevelled-1 (DVL1), Dishevelled-3 (DVL3), E-cadherin (CDH1) and beta-catenin (CTNNB1). Protein expressions and localizations were analyzed by immunohistochemistry. Genetic alterations of E-cadherin were tested by polymerase chain reaction (PCR)/loss of heterozygosity (LOH). Heteroduplex was used to investigate mutations in beta-catenin. DVL1 and DVL3 showed over expression in brain metastasis in 87.1% and 90.3% of samples respectively. Nuclear staining was observed in 54.8% of cases for DVL1 and 53.3% for DVL3. The main effector of the Wnt signaling, beta-catenin, was up-regulated in 56%, and transferred to the nucleus in 36% of metastases. When DVL1 and DVL3 were up-regulated the number of cases with nuclear beta-catenin significantly increased (p=0.0001). Down-regulation of E-cadherin was observed in 80% of samples. Genetic analysis showed 36% of samples with LOH of the CDH1. In comparison to other lung cancer pathologies, the diagnoses adenocarcinoma and small cell lung cancer (SCLC) were significantly associated to CDH1 LOH (p=0.001). Microsatellite instability was detected in one metastasis from adenocarcinoma. Exon 3 of beta-catenin was not targeted. Altered expression of Dishevelled-1, Dishevelled-3, E-cadherin and beta-catenin were present in brain metastases which indicates that Wnt signaling is important and may contribute to better understanding of genetic profile conditioning lung cancer metastasis to the brain.

Indexed as

Adaptor Proteins, Signal TransducingAgedAged, 80 and overbeta CateninBrain NeoplasmsCadherinsDishevelled ProteinsDown-RegulationFemaleHumansLoss of HeterozygosityLung NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedPhosphoproteinsAdaptor Proteins, Signal Transducingbeta CateninCadherinsDishevelled ProteinsDVL1 protein, humanDVL3 protein, humanPhosphoproteins

Identifiers

PMID24933634
PMCPMC4100173
OpenAlexW2021837858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.